Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2019’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)

– The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects

– The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews the latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with the potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adocia SAS

Aerami Therapeutics

Ahead Therapeutics SL

Akston Biosciences Corp

Algiax Pharmaceuticals GmbH

Allist Shanghai Pharmaceutical Technology Co Ltd

Altheia Science SRL

ALTuCELL

Amarantus Bioscience Holdings Inc

Amarna Therapeutics BV

AmideBio LLC

Anokion SA

apceth Biopharma GmbH

Aphios Corp

Apodemus AB

APT Therapeutics Inc

Aptamer Sciences Inc

Arecor Ltd

Ariddad Therapeutics SL

Artery Therapeutics Inc

AstraZeneca Plc

Atlantic Bio Sci LLC

Auxulin Pharmaceuticals Inc

AVM Biotechnology LLC

Avotres Inc

Axxam SpA

Beta-Cell NV

Biocon Ltd

BioLineRx Ltd

BioLingus AG

Bioorg3.14 LLC

Biozeus Pharmaceutical SA

BirchBioMed Inc

Boehringer Ingelheim International GmbH

Bol Pharma

Boston Therapeutics Inc

Bristol-Myers Squibb Co

BTB Pharma AB

Cancer Prevention Pharmaceuticals Inc

CAR-T (Shanghai) Biotechnology Co Ltd

Carlina Technologies SAS

CellTrans Inc

Chongqing Chenan BioPharm Co Ltd

Compugen Ltd

Cour Pharmaceuticals Development Co Inc

CRISPR Therapeutics AG

Cyteir Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Denceptor Therapeutics Ltd

Dendright Pty Ltd

Diabetology (Products) Ltd

Diamyd Medical AB

Diasome Pharmaceuticals Inc

DiaVacs Inc

Dompe Farmaceutici SpA

Dualogics Corp

Eli Lilly and Co

Endsulin LLC

Ensol Biosciences Inc

Enthera Srl

EpiVax Inc

Evotec SE

Fairbanks Pharmaceuticals Inc

FasCure Therapeutics LLC

Follicum AB

Gan & Lee Pharmaceutical Ltd

Generex Biotechnology Corp

GeNeuro SA

Geropharm

Gubra ApS

Hanmi Pharmaceuticals Co Ltd

Housey Pharmaceutical Research Laboratories LLC

Iltoo Pharma

ImCyse SA

ImmunoMolecular Therapeutics LLC

ImmusanT Inc

Innovimmune Biotherapeutics Inc

Intrexon Corp

Inversago Pharma Inc

Islexa Ltd

Jiangsu Hengrui Medicine Co Ltd

JN Biosciences LLC

Johnson & Johnson

Jortan Pharmaceuticals Inc

Kadimastem Ltd

Kamada Ltd

Kunming Yinnuo Medical Technology Co. Ltd.

L2 Diagnostics LLC

Landos Biopharma Inc

Larix Bioscience LLC

Lexicon Pharmaceuticals Inc

MannKind Corp

Maruho Co Ltd

Medytox Inc

Mercia Pharma Inc

Merck & Co Inc

Metavant Sciences Ltd

MidaSol Therapeutics LP

Neovacs SA

NextCell Pharma AB

Novartis AG

Novo Nordisk AS

OneVax LLC

Op-T-Mune Inc

Oramed Pharmaceuticals Inc

Orgenesis Inc

Orion BioScience Inc

OSE Immunotherapeutics

Pancryos

Pandion Therapeutics Inc

Paras Biopharmaceuticals Finland Oy

Parvus Therapeutics Inc

Pfizer Inc

PharmaCyte Biotech Inc

PharmaIN Corp

PolTREG Sp z o o

Polus Inc

Prometheon Pharma LLC

Protomer Technologies Inc

Provention Bio Inc

Purzer Pharmaceutical Co Ltd

Radikal Therapeutics Inc

RedHill Biopharma Ltd

REGiMMUNE Corp

Reliance Life Sciences Pvt Ltd

Remd Biotherapeutics Inc

reMYND NV

Renova Therapeutics Inc

Rezolute Inc

Rubius Therapeutics Inc

SAB Biotherapeutics Inc

Sahane Biotech Inc

Sanofi

Semma Therapeutics Inc

Sensulin LLC

Seraxis Inc

Serpin Pharma LLC

Sihuan Pharmaceutical Holdings Group Ltd

Sotio AS

SQZ Biotechnologies Co

Suntec Medical (Taiwan) Inc

SymbioCellTech LLC

Tetragenetics Inc

Thermalin Diabetes LLC

Toleranzia AB

Tolerion Inc

Tolerx, Inc. (Inactive)

Topas Therapeutics GmbH

Transgene Biotek Ltd

Unicyte AG

Valin Technologies Ltd

Ventria Bioscience

Veralox Therapeutics Inc

ViaCyte Inc

ViCapsys Inc

Virtici LLC

vTv Therapeutics Inc

XERIS Pharmaceuticals Inc

XL-protein GmbH

Yichang Hec Changjiang Pharmaceutical Co Ltd

Youngene Therapeutics Co Ltd

Zealand Pharma AS

Zhejiang Hisun Pharmaceutical Co Ltd